idiopathic pulmonary fibrosis

A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).

A study to test whether BI 1819479 improves lung function in people with IPF.

You will receive either one of three different doses of BI 1819479 or placebo. It will be decided by chance (like flipping a coin) which one you will receive. You will take BI 1819479 and/or placebo as 2 tablets once a day. Neither you nor the study doctor will know the treatment you are getting.

To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0888 or email clinicaltrials@resphealth.uwa.edu.au.

• The trial will run for 6-12 months
• 11-13 clinic visits in Nedlands, plus up to 11 phone visits
• A full health check by our doctors and nurses
• Reimbursement for travel expenses
• Personalised health care with our doctors and nurses